Бастиан Блоэм - Нестареющее тело. Научное исследование о том, как защитить свои тело и мозг и не допустить развития неврологических заболеваний

90. Buchanan RJ, Wang S, Huang C, Simpson P, Manyam BV. Analyses of nursing home residents with Parkinson’s disease using the minimum data set. Parkinsonism & Related Disorders. 2002;8(5):369–380; Ornstein KA, Leff B, Covinsky KE, et al. Epidemiology of the homebound population in the United States. JAMA Internal Medicine. 2015;175(7):1180–1186; Mitchell SL, Kiely DK, Kiel DP, Lipsitz LA. The epidemiology, clinical characteristics, and natural history of older nursing home residents with a diagnosis of Parkinson’s disease. Journal of the American Geriatrics Society. 1996;44(4):394–399.

91. Centers for Medicare & Medicaid Services. Medicare & Home Health Care. US Department of Health and Human Services. October 2017. www.medicare.gov/sites/default/files/2018-07/10969-medicare-and-home-health-care.pdf; Your Medicare coverage. Medicare.gov. www. medicare.gov/coverage/home-health-services. Accessed March 30, 2019.

92. Woods B. By 2020, 90 % of world’s population aged over 6 will have a mobile phone: report. The Next Web. November 18, 2014. https:// thenextweb.com/insider/2014/11/18/2020-90-worlds-population-aged-6-will-mobile-phone-report. Accessed October 11, 2018.

93. Dorsey ER, Glidden AM, Holloway MR, Birbeck GL, Schwamm LH. Teleneurology and mobile technologies: the future of neurological care. Nature Reviews Neurology. 2018;14:285–297.

94. WHO Model List of Essential Medicines. World Health Organization; April 2015.

95. Clinical trial delays: America’s patient recruitment dilemma. Drug Development Technology. July 18, 2012. www.drugdevelopment-technology.com/features/featureclinical-trial-patient-recruitment. Accessed March 30, 2019.

96. Fox Trial Finder. The Michael J. Fox Foundation for Parkinson’s Research. https://foxtrialfinder.michaeljfox.org. Accessed March 30, 2019.

97. Why Clinical Trials? The Michael J. Fox Foundation for Parkinson’s Research.https://files.michaeljfox.org/WhyClinicalTrials.pdf. Accessed January 3, 2019; Schneider MG, Swearingen CJ, Shulman LM, Ye J, Baumgarten M, Tilley BC. Minority enrollment in Parkinson’s disease clinical trials. Parkinsonism & Related Disorders. 2009;15(4):258–262.

98. Bot BM, Suver C, Neto EC, et al. The mPower study, Parkinson disease mobile data collected using ResearchKit. Scientific Data. 2016;3:160011.

99. Fox Insight. The Michael J. Fox Foundation for Parkinson’s Research. https://foxinsight.michaeljfox.org. Accessed January 6, 2019.

100. Berg D, Postuma RB, Adler CH, et al. MDS research criteria for prodromal Parkinson’s disease. Movement Disorders. 2015;30(12):1600–1611.

101. P earson SD, Rawlins MD. Quality, innovation, and value for money: NICE and the British National Health Service. JAMA. 2005;294(20):2618–2622.

102. Weintraub A. How to cover Novartis’ $475K CAR-T drug Kymriah? A “new payment model” is the only way, Express Scripts says. FiercePharma. September 22, 2017. www.fiercepharma.com/financials/ car-t-and-other-gene-therapies-need-new-payment-model-says-express-scripts. Accessed January 6, 2019; Rosenblatt M, Termeer H. Reframing the conversation on drug pricing. NEJM Catalyst. November 20, 2017. https://catalyst.nejm.org/reframing-conversation-drug-pricing. Accessed June 28, 2019.

103. Danzon PM, Towse A. Differential pricing for pharmaceuticals: reconciling access, R&D and patents. International Journal of Health Care Finance and Economics. 2003;3(3): 183–205; Hammer PJ. Differential pricing of essential AIDS drugs: markets, politics and public health. Journal of International Economic Law. 2002;5(4):883–912.

1. Pei, S., Kandula, S. & Shaman, J. Differential Effects of Intervention Timing on COVID-19 Spread in the United States. medRxiv. 2020.

2. Pesticide National Synthesis Project: Estimated annual agricultural pesticide use. US Geological Survey, www.water.usgs.gov/nawqa/pnsp/ usage/maps/show_map.php?year=2017& map=PARAQUAT&hilo=H. Updated June 18, 2020, Accessed October 25, 2020.

3. Meyer, B. Update from D.C.: EPA Allows Usage of Hazardous Pesticide

Paraquat to Continue in the U.S.. Michael J, Fox Foundation . October 26, 2020. www.michaeljfox.org/news/update-dc-epa-allows-usage-

hazardous-pesticide-paraquat-continue-us. Accessed November 2, 2020.

4. Martin, J. TOXMAP, federal database allowing public to track U.S. pollution, shut down after 15 years by National Library of Medicine. Newsweek Digital, December 24 2019. www.newsweek.com/ toxmap-federal-database-allowing-public-track-us-pollution-shut-down-after-15-years-trump-1479146. Accessed October 26, 2020.

5. Peters, R., Ee, N., Peters, J., Booth, A., Mudway, I. & Anstey, K. J. Air Pollution and Dementia: A Systematic Review. Journal of Alzheimer’s Disease. 2019;70(s1):S145-S163.

6. Van Der Boom, N. Doek valt definitief voor Mancozeb [ «Манкоцеб точно запретят»]. Boerenbusiness. October 26, 2020. www.boerenbusiness. nl/akkerbouw/ artikel/10889806/doek-valt-definitief-voor-mancozeb.

Accessed November 2, 2020.

7. GovTrack.us. S. 4406 – 116th Congress: Protect America’s Children from Toxic Pesticides Act. 2020. www.govtrack.us/congress/bills/116/ s4406. Accessed October 25, 2020; U.S. Congress, House. Protect America’s Children from Toxic Pesticides Act. HR 7940, 116 thCongress. Introduced August 4, 2020. www.congress.gov/bill/116th-congress/house-bill/7940/all-info?r=7&s=1. Accessed October 25, 2020; Udall, Neguse Introduce Landmark Pesticide Reform to Protect Children, Farmworkers and Consumers from Toxic Pesticides. Tom Udall Senator for New Mexico . www.tomudall.senate.gov/news/press-releases/udall-neguse-introduce-landmark-pesticide-reform-to-protect-children-farmworkers-and-consumers-from-toxic-pesticides Accessed October 25, 2020.

8. Marshal, M. How COVID-19 can damage the brain. Nature . Online news feature. 2020;585(1476–4687):342–343. www.nature.com/articles/ d41586-020-02599-5. Accessed October 26, 2020.

9. Cohen, M. E., Eichel, R., Steiner-Birmanns, B., Janah, A., Ioshpa, M., Bar-Shalom, R., Paul, J. J., Gaber, H., Skrahina, V., Bornstein, N. M. & Yahalom, G. A case of probable Parkinson’s disease after SARS-CoV-2 infection. The Lancet Neurology. 2020;19(10):804–805; Faber, I., Brandao, P. R. P., Menegatti, F., De Carvalho Bispo, D. D., Maluf, F. B. & Cardoso, F. Coronavirus Disease 2019 and Parkinsonism: A Non-post-encephalitic Case. Movement Disorders: Official Journal of the Movement Disorder Society. 2020;35(10):1721–1722.

10. The federal response to COVID-19. USAspending.gov. www.usaspending. gov/ disaster/covid-19. Accessed October 25, 2020.

11. Estimates of funding for various research, condition, and disease categories (RCDC). NIH Research Portfolio Online Reporting Tools. February 24, 2020. www.report.nih.gov/categorical_spending.aspx. Accessed October 25. 2020.

12. Verma, S. Early impact of CMS expansion of Medicare teleheath during COVID-19. Health Affairs Blog. July 15, 2020. www.healthaffairs.org/ do/10.1377/hblog20200715.454789/full/ Accessed October 25, 2020.

13. Cilia, R., Mancini, F., Bloem, B. R. & Eleopra, R. Telemedicine for parkinsonism: A two-step model based on the COVID-19 experience in Milan, Italy. Parkinsonism & Related Disorders. 2020;75:130–132; Bloem, B. R., Dorsey, E. R. & Okun, M. S. The Coronavirus Disease 2019 Crisis as Catalyst for Telemedicine for Chronic Neurological Disorders. JAMA Neurology. 2020;77(8):927–928.

14. Lam, K., Lu, A. D., Shi, Y. & Covinsky, K. E. Assessing Telemedicine Unreadiness Among Older Adults in the United States During the COVID-19 Pandemic. JAMA Internal Medicine. 2020;180(10):1389–1391.

15. Dahodwala, N., Siderowf, A., Xie, M., Noll, E., Stern, M. & Mandell, D. S. Racial differences in the diagnosis of Parkinson’s disease. Movement Disorders: Official Journal of the Movement Disorder Society. 2020;24(8):1200–1205; Dahodwala, N., Xie, M., Noll, E., Siderowf, A. & Mandell, D. S. Treatment disparities in Parkinson’s disease. Annals of Neurology, 2009;66(2): 142–145.

16. Hobbs, T. D. & Hawkins, L. The results are in for remote learning: it didn’t work. Wall Street Journal . June 5, 2020. www.wsj.com/articles/ schools-coronavirus-remote-learning-lockdown-tech-11591375078. Accessed October 25, 2020.

Рэй Дорси –профессор неврологии и руководитель Центра Здоровье + Технологии (Center for Health + Technology) в Университете Рочестера (University of Rochester). В течение последних десяти лет активно использует телемедицину для улучшения качества медицинского обслуживания пациентов с болезнью Паркинсона. Его исследования публикуются в различных неврологических, медицинских и экономических журналах, о них рассказывают на крупнейшей радиостанции NPR, пишут в Wall Street Journa и New York Time. Ранее Дорси руководил отделением болезни Паркинсона в Медицинской школе Университета Джона Хопкинса ( Johns Hopkins Medicine), а также работал консультантом в McKinsey & Company.

Тодд Шерер– генеральный директор Фонда Майкла Дж. Фокса (The Michael J. Fox Foundation for Parkinson’s Research), самой крупной и уважаемой частной организации, которая занимается финансированием исследований болезни Паркинсона. По профессии Шерер нейробиолог. В Университете Эмори (Emory University) он провел первые исследования, которые указали на наличие связи между распространенными пестицидами и болезнью Паркинсона. Получил степень доктора философии (PhD) в Университете Вирджинии (University of Virginia), а степень бакалавра наук (BS) – в Университете Дьюка (Duke University).

Майкл С. Окун –профессор и председатель отделения неврологии в Университете Флориды (University of Florida). Один из ведущих исследователей болезни Паркинсона. Внес вклад в усовершенствование хирургических методов лечения заболевания. Занимает должность медицинского директора Parkinson’s Foundation, самой крупной организации по оказанию помощи и защите прав пациентов с болезнью Паркинсона. Написал более пятисот научных статей. Автор книги Parkinsons Treatment: 10 Secrets to a Happier Life («10 секретов надежды и счастливой жизни с болезнью Паркинсона»), которая была переведена на двадцать языков. Книга пользуется большой популярностью у пациентов с болезнью Паркинсона и их родных.